Literature DB >> 24645976

Her2 expression and gene amplification is rarely detectable in patients with oral squamous cell carcinomas.

Henning Hanken1, Robert Gaudin, Alexander Gröbe, Meike Fraederich, Wolfgang Eichhorn, Ralf Smeets, Ronald Simon, Guido Sauter, Katharina Grupp, Jacob R Izbicki, Susanne Sehner, Max Heiland, Marco Blessmann.   

Abstract

PURPOSE: Her2 (ErbB2) transforms cells when overexpressed and is an important therapeutic target in breast cancer. Contrary to breast cancer, studies on Her2 overexpression and gene amplification in squamous cell carcinomas of the head and neck region described largely different results. This study was undertaken to learn more on the prevalence and clinical significance of HER2 amplification and overexpression in squamous cell carcinomas of the head and neck.
MATERIALS AND METHODS: Her2 expression and gene amplification was analyzed by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) on two tissue microarrays composed of 427 squamous cell carcinomas of the head and neck region and 222 oral squamous cell carcinomas. Results were compared with clinicopathological features.
RESULTS: Her2 expression and gene amplification was rarely detectable in squamous cell carcinomas of the head and neck region and unrelated to tumor phenotype or survival of the patients with oral squamous carcinoma. DISCUSSION: Our results demonstrate that Her2 protein and gene amplification was only detectable in a small subset of squamous cell carcinomas of the head and neck region as well as oral squamous cell carcinomas. However, it can be speculated that those few patients with Her2 overexpressing and gene amplificated tumors may possibly benefit from an anti-Her2 therapy.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Her2; fluorescence in situ hybridization; head and neck squamous cell carcinoma; immunohistochemistry; oral squamous cell carcinomas

Mesh:

Substances:

Year:  2014        PMID: 24645976     DOI: 10.1111/jop.12173

Source DB:  PubMed          Journal:  J Oral Pathol Med        ISSN: 0904-2512            Impact factor:   4.253


  8 in total

1.  Hormone receptors AR, ER, PR and growth factor receptor Her-2 expression in oral squamous cell carcinoma: Correlation with overall survival, disease-free survival and 10-year survival in a high-risk population.

Authors:  Yumna Adnan; Syed Muhammad Adnan Ali; Muhammad Sohail Awan; Romana Idress; Muhammad Ozair Awan; Hasnain Ahmed Farooqui; Hammad Afzal Kayani
Journal:  PLoS One       Date:  2022-05-11       Impact factor: 3.752

2.  A phosphoarray platform is capable of personalizing kinase inhibitor therapy in head and neck cancers.

Authors:  Konrad Klinghammer; James Keller; Jonathan George; Jens Hoffmann; Edward L Chan; Michael J Hayman
Journal:  Int J Cancer       Date:  2017-10-04       Impact factor: 7.396

3.  Molecular Targeting of Her-2/neu Protein Is Not Recommended as an Adjuvant Therapy in Oral Squamous Cell Carcinoma and Oral Lichen Planus.

Authors:  Maryam Kouhsoltani; Amirala Aghbali; Behrooz Shokoohi; Ronak Ahmadzadeh
Journal:  Adv Pharm Bull       Date:  2015-12-31

4.  Identification of Targetable ERBB2 Aberrations in Head and Neck Squamous Cell Carcinoma.

Authors:  Andrew C Birkeland; Megan Yanik; Brittny N Tillman; Megan V Scott; Susan K Foltin; Jacqueline E Mann; Nicole L Michmerhuizen; Megan L Ludwig; Morgan M Sandelski; Christine M Komarck; Thomas E Carey; Mark E P Prince; Carol R Bradford; Jonathan B McHugh; Matthew E Spector; J Chad Brenner
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2016-06-01       Impact factor: 6.223

Review 5.  The potential of liposomes with carbonic anhydrase IX to deliver anticancer ingredients to cancer cells in vivo.

Authors:  Huei Leng Helena Ng; Aiping Lu; Ge Lin; Ling Qin; Zhijun Yang
Journal:  Int J Mol Sci       Date:  2014-12-24       Impact factor: 5.923

6.  NIR Photodynamic Destruction of PDAC and HNSCC Nodules Using Triple-Receptor-Targeted Photoimmuno-Nanoconjugates: Targeting Heterogeneity in Cancer.

Authors:  Shazia Bano; Girgis Obaid; Joseph W R Swain; Marina Yamada; Brian W Pogue; Kenneth Wang; Tayyaba Hasan
Journal:  J Clin Med       Date:  2020-07-27       Impact factor: 4.241

7.  Expression of HER-2/neu in Oral Squamous Cell Carcinoma.

Authors:  Sana Mirza; Naila Hadi; Shahid Pervaiz; Sultan Zeb Khan; Sameer A Mokeem; Tariq Abduljabbar; Nawwaf Al-Hamoudi; Fahim Vohra
Journal:  Asian Pac J Cancer Prev       Date:  2020-05-01

8.  A defucosylated anti‑CD44 monoclonal antibody 5‑mG2a‑f exerts antitumor effects in mouse xenograft models of oral squamous cell carcinoma.

Authors:  Junko Takei; Mika K Kaneko; Tomokazu Ohishi; Hideki Hosono; Takuro Nakamura; Miyuki Yanaka; Masato Sano; Teizo Asano; Yusuke Sayama; Manabu Kawada; Hiroyuki Harada; Yukinari Kato
Journal:  Oncol Rep       Date:  2020-08-14       Impact factor: 3.906

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.